Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus

Rainer W G Gruessner, David E R Sutherland, Raja Kandaswamy, Angelika C Gruessner

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

BACKGROUND. A pancreas transplant alone (PTA) in a nonuremic patient with brittle diabetes mellitus remains a rare procedure because the tradeoff for insulin independence is lifelong immunosuppression. METHODS. Herein we report our results at the University of Minnesota of 513 PTAs from December 17, 1966, through December 31, 2006. Of these recipients, 87% had previously experienced hypoglycemic unawareness and 23% experienced coma and/or seizures. These transplants spanned four immunosuppressive eras: pre-cyclosporine A (pre-CsA) era (16%), CsA era (23%), tacrolimus (TAC) era (47%), and calcineurin-inhibitor (CNI)-free era (14%). RESULTS. The overall patient survival rate at 1 year posttransplant was about 95%; at 5 years, it was 90%. The pancreas graft survival rate at 1 year increased significantly from the pre-CsA era (31%) to the TAC era (75%), thanks to a significant decline in immunologic and technical failures. The CNI-free protocol, because of its high infection and hematologic infection rate, did not further improve outcome. Risk factors for subsequent kidney failure (13% at 5 years posttransplant) were serum creatinine levels >1.5 mg/dl at the time of the pancreas transplant and recipient age <30 years. CONCLUSIONS. A technically successful PTA is currently the only treatment option that allows nonuremic patients with brittle diabetes to become insulin-independent in the long term.

Original languageEnglish (US)
Pages (from-to)42-47
Number of pages6
JournalTransplantation
Volume85
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Type 1 Diabetes Mellitus
Pancreas
Transplants
Tacrolimus
Cyclosporine
Survival Rate
Insulin
Graft Survival
Immunosuppressive Agents
Coma
Infection
Hypoglycemic Agents
Immunosuppression
Renal Insufficiency
Creatinine
Seizures
Serum
Calcineurin Inhibitors
Therapeutics

Keywords

  • Brittle diabetes mellitus
  • Hypoglycemic unawareness
  • Solitary pancreas transplant

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. / Gruessner, Rainer W G; Sutherland, David E R; Kandaswamy, Raja; Gruessner, Angelika C.

In: Transplantation, Vol. 85, No. 1, 01.2008, p. 42-47.

Research output: Contribution to journalArticle

@article{3748eea333c74fc0875bca75309c1ae7,
title = "Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus",
abstract = "BACKGROUND. A pancreas transplant alone (PTA) in a nonuremic patient with brittle diabetes mellitus remains a rare procedure because the tradeoff for insulin independence is lifelong immunosuppression. METHODS. Herein we report our results at the University of Minnesota of 513 PTAs from December 17, 1966, through December 31, 2006. Of these recipients, 87{\%} had previously experienced hypoglycemic unawareness and 23{\%} experienced coma and/or seizures. These transplants spanned four immunosuppressive eras: pre-cyclosporine A (pre-CsA) era (16{\%}), CsA era (23{\%}), tacrolimus (TAC) era (47{\%}), and calcineurin-inhibitor (CNI)-free era (14{\%}). RESULTS. The overall patient survival rate at 1 year posttransplant was about 95{\%}; at 5 years, it was 90{\%}. The pancreas graft survival rate at 1 year increased significantly from the pre-CsA era (31{\%}) to the TAC era (75{\%}), thanks to a significant decline in immunologic and technical failures. The CNI-free protocol, because of its high infection and hematologic infection rate, did not further improve outcome. Risk factors for subsequent kidney failure (13{\%} at 5 years posttransplant) were serum creatinine levels >1.5 mg/dl at the time of the pancreas transplant and recipient age <30 years. CONCLUSIONS. A technically successful PTA is currently the only treatment option that allows nonuremic patients with brittle diabetes to become insulin-independent in the long term.",
keywords = "Brittle diabetes mellitus, Hypoglycemic unawareness, Solitary pancreas transplant",
author = "Gruessner, {Rainer W G} and Sutherland, {David E R} and Raja Kandaswamy and Gruessner, {Angelika C}",
year = "2008",
month = "1",
doi = "10.1097/01.tp.0000296820.46978.3f",
language = "English (US)",
volume = "85",
pages = "42--47",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus

AU - Gruessner, Rainer W G

AU - Sutherland, David E R

AU - Kandaswamy, Raja

AU - Gruessner, Angelika C

PY - 2008/1

Y1 - 2008/1

N2 - BACKGROUND. A pancreas transplant alone (PTA) in a nonuremic patient with brittle diabetes mellitus remains a rare procedure because the tradeoff for insulin independence is lifelong immunosuppression. METHODS. Herein we report our results at the University of Minnesota of 513 PTAs from December 17, 1966, through December 31, 2006. Of these recipients, 87% had previously experienced hypoglycemic unawareness and 23% experienced coma and/or seizures. These transplants spanned four immunosuppressive eras: pre-cyclosporine A (pre-CsA) era (16%), CsA era (23%), tacrolimus (TAC) era (47%), and calcineurin-inhibitor (CNI)-free era (14%). RESULTS. The overall patient survival rate at 1 year posttransplant was about 95%; at 5 years, it was 90%. The pancreas graft survival rate at 1 year increased significantly from the pre-CsA era (31%) to the TAC era (75%), thanks to a significant decline in immunologic and technical failures. The CNI-free protocol, because of its high infection and hematologic infection rate, did not further improve outcome. Risk factors for subsequent kidney failure (13% at 5 years posttransplant) were serum creatinine levels >1.5 mg/dl at the time of the pancreas transplant and recipient age <30 years. CONCLUSIONS. A technically successful PTA is currently the only treatment option that allows nonuremic patients with brittle diabetes to become insulin-independent in the long term.

AB - BACKGROUND. A pancreas transplant alone (PTA) in a nonuremic patient with brittle diabetes mellitus remains a rare procedure because the tradeoff for insulin independence is lifelong immunosuppression. METHODS. Herein we report our results at the University of Minnesota of 513 PTAs from December 17, 1966, through December 31, 2006. Of these recipients, 87% had previously experienced hypoglycemic unawareness and 23% experienced coma and/or seizures. These transplants spanned four immunosuppressive eras: pre-cyclosporine A (pre-CsA) era (16%), CsA era (23%), tacrolimus (TAC) era (47%), and calcineurin-inhibitor (CNI)-free era (14%). RESULTS. The overall patient survival rate at 1 year posttransplant was about 95%; at 5 years, it was 90%. The pancreas graft survival rate at 1 year increased significantly from the pre-CsA era (31%) to the TAC era (75%), thanks to a significant decline in immunologic and technical failures. The CNI-free protocol, because of its high infection and hematologic infection rate, did not further improve outcome. Risk factors for subsequent kidney failure (13% at 5 years posttransplant) were serum creatinine levels >1.5 mg/dl at the time of the pancreas transplant and recipient age <30 years. CONCLUSIONS. A technically successful PTA is currently the only treatment option that allows nonuremic patients with brittle diabetes to become insulin-independent in the long term.

KW - Brittle diabetes mellitus

KW - Hypoglycemic unawareness

KW - Solitary pancreas transplant

UR - http://www.scopus.com/inward/record.url?scp=38149100450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149100450&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000296820.46978.3f

DO - 10.1097/01.tp.0000296820.46978.3f

M3 - Article

C2 - 18192910

AN - SCOPUS:38149100450

VL - 85

SP - 42

EP - 47

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -